MD4851B1 - Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi - Google Patents

Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Info

Publication number
MD4851B1
MD4851B1 MDA20210032A MD20210032A MD4851B1 MD 4851 B1 MD4851 B1 MD 4851B1 MD A20210032 A MDA20210032 A MD A20210032A MD 20210032 A MD20210032 A MD 20210032A MD 4851 B1 MD4851 B1 MD 4851B1
Authority
MD
Moldova
Prior art keywords
steroids
overcoming resistance
glutarimide derivative
patients
treating
Prior art date
Application number
MDA20210032A
Other languages
English (en)
Russian (ru)
Other versions
MD20210032A2 (ro
MD4851C1 (ro
Inventor
Владимир НЕБОЛЬСИН
Original Assignee
Ооо "Валента-Интеллект"
ОУ НЕБОЛЬСИН Владимир Евгеньевич
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Валента-Интеллект", ОУ НЕБОЛЬСИН Владимир Евгеньевич filed Critical Ооо "Валента-Интеллект"
Publication of MD20210032A2 publication Critical patent/MD20210032A2/ro
Publication of MD4851B1 publication Critical patent/MD4851B1/ro
Publication of MD4851C1 publication Critical patent/MD4851C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Invenţia se referă la medicină, în particular, la un medicament nou, eficient pentru tratamentul bolilor, asociate cu semnalizarea aberantă a interferonului gamma, cum ar fi sindromul Sjogren, dermatomiozita, lupusul eritematos sistemic sau scleroza sistemică, precum şi în tratamentul pacienţilor, care suferă de tuse, şi tratamentul tulburărilor la pacienţii cu rezistenţă la steroizi, cum ar fi bolile tractului gastro-intestinal, prin utilizarea compusului 1-(2-(1H-imidazol-4-il)etil)piperidin-2,6-dionă:.
MDA20210032A 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi MD4851C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Publications (3)

Publication Number Publication Date
MD20210032A2 MD20210032A2 (ro) 2021-09-30
MD4851B1 true MD4851B1 (ro) 2023-04-30
MD4851C1 MD4851C1 (ro) 2023-11-30

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
MDA20210050A MD4844C1 (ro) 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
MDA20210032A MD4851C1 (ro) 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MDA20210050A MD4844C1 (ro) 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Country Status (18)

Country Link
US (1) US20220362230A1 (ro)
EP (2) EP3884945A4 (ro)
JP (2) JP2022508167A (ro)
KR (2) KR20210095652A (ro)
CN (2) CN113164464A (ro)
AU (2) AU2019384626A1 (ro)
BR (1) BR112021009801A2 (ro)
CA (1) CA3120882A1 (ro)
CL (2) CL2021001316A1 (ro)
EA (1) EA201992646A1 (ro)
GE (1) GEP20237467B (ro)
IL (2) IL297533A (ro)
MD (2) MD4844C1 (ro)
MX (2) MX2021006032A (ro)
PH (1) PH12021551152A1 (ro)
RU (1) RU2712281C1 (ro)
WO (1) WO2020106191A1 (ro)
ZA (2) ZA202104247B (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (ro) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf, De
CA2129114A1 (en) * 1992-02-07 1993-08-19 Albert M. Kligman Methods of treating inflammatory dermatoses
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
BR112013020498A2 (pt) * 2011-02-10 2016-08-09 Genqual Corp método para determinar a capacidade de resposta a inibidores e para tratamento de um sujeito
CN110229140B (zh) * 2013-04-12 2022-06-10 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Also Published As

Publication number Publication date
MD20210032A2 (ro) 2021-09-30
ZA202104247B (en) 2023-03-29
MD4844C1 (ro) 2023-09-30
AU2019384626A1 (en) 2021-07-15
RU2712281C1 (ru) 2020-01-28
JP2022508167A (ja) 2022-01-19
CN114652721A (zh) 2022-06-24
ZA202210444B (en) 2023-01-25
GEP20237467B (en) 2023-02-10
BR112021009801A2 (pt) 2022-03-03
AU2022256212A1 (en) 2022-12-08
EP4218758A3 (en) 2023-08-23
CA3120882A1 (en) 2020-05-28
MD20210050A2 (ro) 2021-12-31
JP2023015333A (ja) 2023-01-31
EP4218758A2 (en) 2023-08-02
WO2020106191A1 (ru) 2020-05-28
KR20210095652A (ko) 2021-08-02
IL297533A (en) 2022-12-01
CN113164464A (zh) 2021-07-23
MX2021006032A (es) 2021-07-06
MD4851C1 (ro) 2023-11-30
US20220362230A1 (en) 2022-11-17
MX2022013503A (es) 2022-11-16
PH12021551152A1 (en) 2021-10-25
EA201992646A1 (ru) 2020-05-31
CL2021001316A1 (es) 2021-10-29
MD4844B1 (ro) 2023-02-28
IL283317A (en) 2021-07-29
EP3884945A4 (en) 2022-11-23
KR20220162821A (ko) 2022-12-08
EP3884945A1 (en) 2021-09-29
CL2022000683A1 (es) 2022-10-28

Similar Documents

Publication Publication Date Title
MX2021005691A (es) Formulaciones de farmacos resistentes al alcohol.
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MD4851C1 (ro) Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
MX2023010326A (es) Inhibidores de atf6 y sus usos.
MD20160138A2 (ro) Combinaţie
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
MX2023000100A (es) Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
ATE537143T1 (de) Spiro(5.5)undecan derivate
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
AU2018320416A8 (en) Pyridylpyridone compounds
MX2021000966A (es) Piridopirimidinas como inhibidores del receptor de histamina h4.
GB201904374D0 (en) Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
AU2018320419A1 (en) Morpholinylpyridone compounds
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
MX2021003274A (es) Combinacion farmaceutica para el tratamiento de cancer.
MX2022004219A (es) Moduladores de atf6 y usos de los mismos.
WO2020106454A3 (en) Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Legal Events

Date Code Title Description
GB9A Change of applicant (patent for invention)

Owner name: LTD VALENTA-INTELLEKT, RU UL. RYABINOVAYA, D. 26 BUILDING 10, CAB. 6-26, MOSCOW, 121471, FEDERATIA RUSA;IP NEBOLSIN VLADIMIR EVGHENIEVICH, RU STR. GOLITSYNSKAYA, 457, ISTRINSKIY R-N, D. BORZYE, MOSKOVSKAYA OBL., 143581, FEDERATIA RUSA

Free format text: PREVIOUS APPLICANT: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES",RU 121205, MOSCOW, MOZHAISKY MUNICIPAL DISTRICT, TERRITORY OF THE SKOLKOVO INNOVATION CENTER, BOLSHOY BOULEVARD, HOUSE 42, BUILDING 1, FLOOR 3, ROOM 1280, FEDERATIA RUSA

FG4A Patent for invention issued